))
A Discussion with Brian Finn of Findell Capital: Biotech Investing, Liquidia & ProQR
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on October 16, 2023 23:24 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337249290 series 3380517
Innhold levert av Encode Ideas, L.P., Encode Ideas, and L.P.. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Encode Ideas, L.P., Encode Ideas, and L.P. eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
An interview with Brian Finn of Findell Capital, where we discuss his perspective on small-cap investing. During the interview, we discuss two of Brian's favorite health care names, Liquidia and ProQR, as well as his previous success with MiMedx. To learn more about Findell Capital please visit their website https://findell.us/
Companies discussed during the podcast;
- Liquidia Corporation (Nasdaq: LQDA)
- ProQR Therapeutics N.V. (Nasdaq: PRQR)
- MiMedx Group Inc (Nasdaq: MDXG)
- United Therapeutics Corporation (Nasdaq: UTHR)
- MannKind Corporation (Nasdaq: MNKD)
- Editas Medicine Inc (Nasdaq: EDIT)
7 episoder
Del
